|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our finding of tumor-specific patterns of NR expression, as well as significant differences in NR expression between BRAF(V600E) and wild type BRAF PTC, provides a basis for further mechanistic studies and highlights potential novel therapeutic targets for this malignancy.
|
24559275 |
2014 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The AUS-NA subcategory was associated with the highest risk of malignancy and the greatest frequency of BRAF V600E (substitution of valine to glutamic acid at position 600) mutation.
|
24619974 |
2014 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Hence, this IHC detection is sensitive for clinic uses as a simple, fast, inexpensive, and reliable method to screen cancer patients for the BRAF(V600E) mutation and could be easily adapted for use in most hospital pathology laboratories.
|
24563339 |
2014 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Morphological parameters able to predict BRAF(V600E) -mutated malignancies on thyroid fine-needle aspiration cytology: Our institutional experience.
|
25156883 |
2014 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The therapeutic significance of this inhibition in cancer cells was shown while unraveling a novel mechanism of resistance to B-RAF(V600E/K) inhibitors.
|
23651636 |
2013 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
We calculated and compared the diagnostic performances of cytology and cytology with BRAF(V600E) mutation analysis to detect malignancy among thyroid nodules according to ultrasound features and size.
|
23717622 |
2013 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Right-sided colon tumors more frequently have BRAF (p.V600E) mutations and have higher methylation grades when compared to left-sided malignancies.
|
24244575 |
2013 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Besides confirming the constant presence of BRAF-V600E in all patients with hairy cell leukemia, we observed ubiquitous phospho-ERK expression in this malignancy.
|
23349307 |
2013 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF V600E mutation was associated with an advanced stage of cancer (P = .045) and was found to be associated with poor prognostic factors.
|
23690118 |
2013 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Expression analysis of B-Raf oncogene in V600E-negative benign and malignant tumors of the thyroid gland: correlation with late disease onset.
|
23263826 |
2013 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Approximately 75% of the cases were cytologically diagnosed as being positive for malignancy and these cases were associated with both the classic and tall cell variants of PTC at the time of resection, a greater likelihood of extrathyroidal extension, and the V600E type of BRAF mutation.
|
22887810 |
2013 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
These data suggest additive, combinatorial activity between radiation and PLX4720 in cancers carrying BRAF V600E mutations.
|
23354848 |
2013 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF(V600E) mutation was identified in 13 patients (4%), 12 of whom had either cytologic atypia or were Bethesda category V. Three percent of Bethesda category III or IV nodules that were malignant harbored the mutation compared with 42% of Bethesda category V malignancies.
|
23280049 |
2013 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E is an emerging drug target in lung cancer, but the clinical significance of non-V600 BRAF mutations in lung cancer and other malignancies is less clear.
|
24035431 |
2013 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF-V600E mutations are found in a broad spectrum of cancer types and can be successfully targeted by specific therapeutic compounds.
|
23343956 |
2013 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The usefulness of immunohistochemistry (IHC) as a new approach for the detection of BRAF V600E in cancer patients has been recently reported.
|
23927882 |
2013 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Detection of the BRAF V600E mutation is therefore a useful adjunct in the differential diagnosis of HCL and HCL variant and highlights the value of a multifaceted approach to the diagnosis of this malignancy.
|
22313586 |
2012 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Recent developments in v-raf murine sarcoma viral oncogene homolog B1 (BRAF)(V600E)-specific small molecule inhibitors and their clinical approval for other cancer types could turn BRAF(V600E) into a promising molecular predictor of outcome in pilocytic astrocytomas, given a treatment with a mutation-specific BRAF inhibitor is applied.
|
23160425 |
2012 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
In conclusion, we show that SkE, a very potent inhibitor of B-Raf-V600E, is highly effective against cancer cell lines that exhibit constitutive activation of the ERK1/2 pathway.
|
23518796 |
2012 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The aims of this study were to evaluate the utility of US-guided FNAB in the diagnostic assessment of nodules with or without clinical/US features suggestive for malignancy and to investigate the additional contribution of BRAF V600E mutation analysis in the detection of differentiated thyroid cancer.
|
22535974 |
2012 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF inhibitor vemurafenib has become an important treatment option for melanoma patients, the majority of whom have a BRAF(V600E) mutation driving their malignancy.
|
23074264 |
2012 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
These data demonstrate that clonal BRAF(V600E) is a rare occurrence in PTC, although frequently this cancer consists of a mixture of tumor cells with wild-type and mutant BRAF.
|
22170714 |
2012 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Identification of BRAF(V600E) in thyroid neoplasia may be useful because it is specific for malignancy, connotes a worse prognosis, and is the target of novel therapies currently under investigation.
|
22997209 |
2012 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
A set of 668 stage II and III CC samples from the PETACC-3 (Pan-European Trails in Alimentary Tract Cancers) clinical trial were used to assess differential gene expression between c.1799T>A (p.V600E) BRAF mutant and non-BRAF, non-KRAS mutant cancers (double wild type) and to construct a gene expression-based classifier for detecting BRAF mutant samples with high sensitivity.
|
22393095 |
2012 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Notch functions as an oncogene or tumor suppressor according to the type of malignancy, and the BRAF(V600E) mutation is commonly observed in thyroid cancer.
|
22118425 |
2012 |